Skuldtech has been founded in 1999. Since then, several collaborators, scientific consultants, private and capital investors have joined the company.

The company was founded by Didier Ritter and Dr David Piquemal, with the support of Pr Jacques Marti and Pr Therese Commes-Maerten from Montpellier University.

Skuldtech is supported by Oseo, the French SME funding organization, and has been granted a Research Tax Relief ("Agrément Crédit Impôt Recherche") by the French Ministry of Research and Technology.

Since 2004, Skuldtech has received funding from national and international anti-doping agencies (WADA, USADA, AFLD) to identify and validate in a clinical setting the biomarkers associated with erythropoietin (EPO) drug abuse.

In 2006, Skuldtech and Roche Diagnostics have issued an Application Note concerning rapid and accurate gene profiles determined with the "Genome Sequencer System" developed by 454 Life Sciences.

Since 2007, Skuldtech has received grants from the European Union for new diagnosis development, the analysis of animal venom as new drug leads (in collaboration with the J. Craig Venter Institute) and for the study of host-pathogenic interactions in the leishmania case.

Moreover, Skuldtech is positioned since several years in the field of “personalized medicine,” which takes people’s biological and physiological differences into account in order to administer the most effective treatments, adapted to match the profile of each patient. Hence, the company participates in several projects, notably a clinical research program that will make it possible to identify patients with chronic leukemia and high prognostic factors of survival. Skuldtech is also a partner in the APAS-IPK project, led by the drug discovery company AB Science, in which it will develop a “companion” diagnostic tool that identifies pancreatic cancer patients with positive response to the molecule developed by AB Science (now in phase III trials). In addition, Skuldtech recently became a partner in the NP03 project led by Medesis Pharma, a “drug delivery” company, in which it will develop another companion diagnostic tool that identifies patients with Huntington’s disease with positive response to the treatment developed by Medesis Pharma (now in phase II trials).

Skuldtech is also partner of several French bioclusters of excellence in Human Health and Life Science: GSO Canceropole, Eurobiomed/Euromediag and Biomeridies.